Yayın: Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study
| dc.contributor.author | Turhal, N. S. | |
| dc.contributor.author | Hasan Şenol Çoşkun | |
| dc.contributor.author | Faysal Dane | |
| dc.contributor.author | Bülent Karabulut | |
| dc.contributor.author | Levent Korkmaz | |
| dc.contributor.author | Mustafa Karaağaç | |
| dc.contributor.author | Devrim Çabuk | |
| dc.contributor.author | Senem Karabulut | |
| dc.contributor.author | Nuri Faruk Aykan | |
| dc.contributor.author | Hatice Doruk | |
| dc.contributor.author | Nilüfer Avcı | |
| dc.contributor.author | N. S. Turhal | |
| dc.contributor.orcid | 0000-0003-2335-3354 | |
| dc.contributor.orcid | 0000-0003-2969-7561 | |
| dc.contributor.orcid | 0000-0001-6584-902X | |
| dc.contributor.orcid | 0000-0002-1949-8334 | |
| dc.contributor.orcid | 0000-0001-6931-6896 | |
| dc.contributor.orcid | 0000-0003-4533-0620 | |
| dc.contributor.orcid | 0000-0002-7871-6311 | |
| dc.contributor.orcid | 0000-0003-4740-9973 | |
| dc.contributor.orcid | 0000-0002-5472-3218 | |
| dc.contributor.orcid | 0000-0002-1013-5676 | |
| dc.date.accessioned | 2025-11-13T22:20:32Z | |
| dc.date.issued | 2016-04-29 | |
| dc.identifier.doi | https://doi.org/10.1007/s12029-016-9823-7 | |
| dc.identifier.endpage | 272 | |
| dc.identifier.issn | 1941-6628 | |
| dc.identifier.issue | 3 | |
| dc.identifier.openalex | W2342916534 | |
| dc.identifier.startpage | 264 | |
| dc.identifier.uri | https://hdl.handle.net/11421/13865 | |
| dc.identifier.uri | https://doi.org/10.1007/s12029-016-9823-7 | |
| dc.identifier.volume | 47 | |
| dc.language.iso | en | |
| dc.relation.ispartof | Journal of Gastrointestinal Cancer | |
| dc.rights | restrictedAccess | |
| dc.subject | Bevacizumab | |
| dc.subject | Medicine | |
| dc.subject | Internal medicine | |
| dc.subject | Irinotecan | |
| dc.subject | Oxaliplatin | |
| dc.subject | Colorectal cancer | |
| dc.subject | Oncology | |
| dc.subject | Capecitabine | |
| dc.subject | KRAS | |
| dc.subject | Chemotherapy | |
| dc.subject | Cetuximab | |
| dc.subject | Progression-free survival | |
| dc.subject | Cancer | |
| dc.subject.sdg | 3 | |
| dc.title | Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| local.authorid.openalex | A5064011743 |
